Hepatitis C Clinical Trial
Official title:
A Randomized, Active-Control Phase II Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic Hepatitis C Virus Genotype 1 Infection
This will be a randomized, open-label, active-control Phase II pilot trial of bavituximab
combined with ribavirin for initial treatment of chronic HCV genotype 1 infection. Eligible
patients with normal coagulation, hematological, and renal function will undergo a
screening/washout period of up to 28 days, followed by randomization to receive weekly
bavituximab or PEG-IFN alpha-2a therapy for 12 weeks, both with twice-daily ribavirin.
The primary endpoint of this study is the proportion of patients who show a greater than or
equal to 2-log10 IU reduction in plasma HCV RNA level after 12 weeks of treatment (early
virological response; EVR).
Secondary endpoints include the proportion of patients with an undetectable HCV RNA level
after 12 weeks of treatment; the proportion of patients who show a reduction in HCV RNA
level of greater than or equal to 2 log10 IU after 4 weeks of treatment, viral kinetics for
individual patients over time, and comprehensive evaluation of the safety and tolerability
of bavituximab infusion.
Status | Completed |
Enrollment | 66 |
Est. completion date | February 2012 |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Male or female between the ages of 18 and 65 years 2. Chronic hepatitis C virus (HCV) genotype 1 infection 3. HCV RNA level >10,000 IU/mL 4. Chronic HCV infection, defined as: - Previous documentation of positive HCV serology (HCV antibody or RNA) at least 6 months (24 weeks) previously, or - Positive HCV serology (HCV antibody or RNA) with a prior remote (more than 6 months previously) risk factor for acquisition of HCV or - Historical biopsy consistent with chronic HCV infection 5. No clinically significant abnormalities in hematology, coagulation, or chemistry variables: - Hemoglobin >12 g/dL for women; >13 g/dL for men - Total white cell count >3000/mm3 and absolute neutrophil count >1500/mm3 - Platelets >100,000/mm3 - Prothrombin time (PT) and/or international normalized ratio (INR) less than or equal to 1.2 times the local upper limit of normal (ULN) - Conjugated (direct) bilirubin less than or equal to 1.5 times the ULN - Serum creatinine within normal limits - Thyroid-stimulating hormone (TSH) and free thyroxine (T4) within normal limits 6. Female patients: negative urine pregnancy test 7. Ability to provide informed consent Exclusion Criteria: 1. Previous interferon-based antiviral therapy for chronic HCV infection 2. Previous treatment with known immunogenic drugs 3. Concomitant human immunodeficiency (HIV) or hepatitis B virus (HBV) infection 4. Cause of liver disease other than chronic HCV infection, such as autoimmune or alcoholic liver disease 5. Decompensated clinical liver disease, including a history of encephalopathy, bleeding esophageal or gastric varices, or ascites 6. Recipient of liver or other solid-organ transplantation 7. Evidence of clinically significant bleeding, defined as gross hematuria, hemoptysis, or gastrointestinal bleeding 8. History of bleeding diathesis or coagulopathy (eg, von Willebrand disease or hemophilia) 9. History of thromboembolic events (eg, deep-vein thrombosis [DVT] or pulmonary embolism). Previous central venous catheter-related thrombosis is acceptable if there is resolution recorded at least 12 months before enrollment. 10. Requirement for concurrent treatment with oral or parenteral anticoagulants or hormones (estrogen-containing contraceptives, hormone replacement, antiestrogen agents, progestins) 11. Condition requiring daily therapy with antiplatelet agents (eg, thienopyridines, dipyridamole, cilostazol; cardiovascular prophylaxis with aspirin is allowed) or corticosteroids 12. Investigational therapy within 28 days before the first planned dose of study drug 13. Major surgery within 28 days before the first planned dose of study drug 14. Uncontrolled intercurrent disease (eg, diabetes, hypertension, thyroid disease) 15. Ongoing angina pectoris or other symptoms of coronary artery disease (CAD); history of stroke, or transient ischemic attack (TIA) 16. History of suicidal ideation or attempt 17. Condition requiring treatment (past or current) with coumarin-type agents 18. Cardiac arrhythmia requiring medical therapy 19. Serious nonhealing wound (including wound healing by secondary intention, ulcer, or bone fracture) 20. Cancer, autoimmune disease, or any disease or concurrent therapy known to cause significant alteration in immune function (corticosteroids are allowed before study enrollment and during the study to treat an AE) 21. Female patients and female partners of male patients: pregnancy, lactation, or inability/unwillingness to practice effective contraception |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Georgia | LTD Vakhtang Bochorishvili Anticeptic Centre | Tbilisi |
Lead Sponsor | Collaborator |
---|---|
Peregrine Pharmaceuticals |
Georgia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction in Hepatitis C Virus RNA | The primary endpoint is the proportion of patients who show a greater or equal 2-log(10) IU reduction in HCV RNA level at Study Week 12 (early virological response, EVR). | 12 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
Completed |
NCT03186313 -
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
|
Phase 3 | |
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 |